iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 2001

Identifiers

  • Canonical SMILES:
    Cc1onc(c1C(=O)N1CCN(CC1)c1ccc(cc1Cl)N(=O)=O)-c1ccccc1Cl
  • IUPAC name:
    1-(2-chloro-4-nitrophenyl)-4-[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]piperazine
  • InChi:
    InChI=1S/C21H18Cl2N4O4/c1-13-19(20(24-31-13)15-4-2-3-5-16(15)22)21(28)26-10-8-25(9-11-26)18-7-6-14(27(29)30)12-17(18)23/h2-7,12H,8-11H2,1H3
  • InChiKey:
    MVZDVDKOXKQGDM-UHFFFAOYSA-N

External links


2866163

CHEMBL5415752

External search

Bibliography (1)

Publication Name
Gerritz S. W., Cianci C., Kim S., Pearce B. C., Deminie C., Discotto L., McAuliffe B., Minassian B. F., Shi S., Zhu S., Zhai W., Pendri A., Li G., Poss M. A., Edavettal S., McDonnell P. A., Lewis H. A., Maskos K., Mortl M., Kiefersauer R., Steinbacher S., Baldwin E. T., Metzler W., Bryson J., Healy M. D., Philip T., Zoeckler M., Schartman R., Sinz M., Leyva-Grado V. H., Hoffmann H.-H., Langley D. R., Meanwell N. A., Krystal M.. . Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers Proceedings of the National Academy of Sciences. 2

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 3 0 0

Targets

PPI family Best activity Diseases MMoA
Influenza NP 7.22 influenza Stabilization
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 460.07 g/mol
HBA 8
HBD 0
HBA + HBD 8
AlogP 4.75
TPSA 95.40
RB 4
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 1 3 0 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
10.1073/pnas.1107906108 2 Q1K9H2
Q1K9H2

Cellular assay Antiviral H1N1 A/WSN/33 MDBK pEC50 (half maximal effective concentration, -log10) 7.22
10.1073/pnas.1107906108 2 Q1K9H2
Q1K9H2

Cellular assay Antiviral H1N1 A/Solomon Islands/3/2006 MDBK pEC50 (half maximal effective concentration, -log10) 6.00
10.1073/pnas.1107906108 2 Q1K9H2
Q1K9H2

Cellular assay Antiviral H5N1 A/Gull_PA/4175/83 MDBK pEC50 (half maximal effective concentration, -log10) 7.00
10.1073/pnas.1107906108 2 Q1K9H2
Q1K9H2

Biochemical assay H1N1 A/WSN polymerase pIC50 (half maximal inhibitory concentration, -log10) 6.21
Ta Structure Name Drugbank ID
0.6044 Cloxacillin DB01147
0.5991 Dicloxacillin DB00485
0.5812 Flucloxacillin DB00301
0.5422 Oxacillin DB00713
0.4912 Leflunomide DB01097
0.4110 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE DB06964
0.4106 Cilofexor DB15168
0.4044 Valdecoxib DB00580
0.4000 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide DB06961
0.4000 Parecoxib DB08439
0.3991 PX-102 DB15416
0.3970 N-[4-(2-CHLOROPHENYL)-1,3-DIOXO-1,2,3,6-TETRAHYDROPYRROLO[3,4-C]CARBAZOL-9-YL]FORMAMIDE DB07226
0.3887 Basmisanil DB11877
0.3716 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol DB07601
0.3684 AUY922 DB11881